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Background: Chronic exposure to high glucose-containing peritoneal dialysis
solution and consequent abdominal obesity are potential sources of insulin
resistance in patients requiring prevalent peritoneal dialysis. The aim of this study
was to elucidate the prognostic values of insulin resistance on new-onset cardio-
vascular events in nondiabetic patients undergoing prevalent peritoneal dialysis.
Methods: A total of 201 nondiabetic patients undergoing prevalent peritoneal dialysis
were recruited. Insulin resistance was assessed by homeostatic model assessment of
insulin resistance (HOMA-IR). The primary outcome was new-onset cardiovascular
events during the follow-up period. Cox proportional hazard analysis was performed
to ascertain the independent prognostic value of HOMA-IR for the primary outcome.
Results: The mean age was 53.1 years and male was 49.3% (n¼99). The mean HOMA-
IR was 2.672.1. In multivariate linear regression, body mass index (β¼0.169, P¼0.011),
triglyceride level (β¼0.331, Po0.001), and previous cardiovascular diseases (β¼0.137,
P¼0.029) were still signiﬁcantly associated with HOMA-IR. During a mean follow-up
duration of 36.8716.2 months, the primary outcome was observed in 36 patients
(17.9%). When patients were divided into tertiles according to HOMA-IR, the highest
tertile group showed a signiﬁcantly higher incidence rate for new-onset cardiovascular
events compared to the lower two tertile groups (P¼0.029). Furthermore, multivariate
Cox analysis revealed that HOMA-IR was an independent predictor of the primary
outcome (hazard ratio¼1.18, 95% conﬁdence interval¼1.03–1.35, P¼0.014).
Conclusion: Insulin resistance measured by HOMA-IR was an independent risk factor
for new-onset cardiovascular events in nondiabetic patients undergoing prevalent
peritoneal dialysis.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Publi
c-nd/4.0/).
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Cardiovascular disease (CVD) is the most important and
leading cause of death in those with end-stage renal disease
(ESRD) [1,2]. In the general population, insulin resistance is
related to several risk factors for CVD, including hypertension,shed by Elsevier. This is an open access article under the CC BY-NC-ND
Figure 1. A ﬂow diagram of the study. All patients with ESRD older
than 18 years of age who underwent PD for43 months were initially
screened for enrollment between January 2009 and December 2009.
Excluding 86 patients, a total of 201 patients were enrolled. HD,
hemodialysis; SLE, systemic lupus erythematosus.
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hyperinsulinemia itself and related-insulin resistance are
directly associated with development of CVD [4,5].
In patients with ESRD, many factors including uremia,
chronic inﬂammation, and abnormal adipokines are involved
in the development of insulin resistance. Previous studies
revealed that insulin resistance was prevalent and was an
independent predictor of cardiovascular mortality in nondia-
betic patients with ESRD and on hemodialysis (HD) [6]. In
particular, in patients on peritoneal dialysis (PD), chronic
exposure to high glucose-containing PD solution causes
several hazard events including hypertriglyceridemia, poor
glycemic control, new-onset diabetes, and central obesity [7].
It is likely that these abnormalities aggravate insulin resistance
in patients on PD [7]. Furthermore, a recent study also showed
a relationship between insulin resistance, as assessed by
homeostatic model assessment of insulin resistance (HOMA-
IR), and CVD in patients on PD [8–10]. However, due to the
relatively small sample size and the very low incidence rate of
CVD seen in a previous study, earlier results would beneﬁt
from validation of the predictive role of insulin resistance in a
larger population. Therefore, we investigated whether insulin
resistance determined by HOMA-IR was an independent
predictor of cardiovascular outcome in nondiabetic patients
with ESRD and on PD.Methods
Ethics statement
The study was carried out in accordance with the Declara-
tion of Helsinki and approved by the Institutional Review
Board of Yonsei University Health System (YUHS) Clinical Trial
Center, Seoul, Korea. We obtained informed written consent
from all participants involved in the current study.
Patients
All consecutive nondiabetic patients with ESRD older than
18 years of age who underwent PD for43 months at YUHS
were initially screened for enrollment between January 2009
and December 2009 in this prospective observational study.
Patients were considered eligible if they had no history of
malignancy or chronic inﬂammatory disease such as systemic
lupus erythematosus or rheumatoid arthritis, and had no overt
infection during the 3 months prior to study entry. We also
excluded patients with a history of kidney transplantation, a
history of HD for43 months prior to PD, or a history of CVD
within 3 months prior to study entry (Fig. 1).
Clinical and biochemical data collection
Demographic and clinical data recorded at study entry
included: age, sex, PD duration, primary renal disease, smoking
status, and medication use. Body mass index (BMI) and bio-
chemical data were measured at study enrollment. Patients
were weighed in light clothing, and height was measured with
shoes off. BMI was calculated as weight/height (kg/m2). Diabetes
mellitus was deﬁned as previously described [11]. Blood was
taken after a 12-hour overnight fast, and the following labora-
tory data were measured: hemoglobin, glucose, blood urea
nitrogen, creatinine, albumin, iron proﬁle, triglyceride (TG), totalcholesterol, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol (HDL-C), calcium, phosphorus, and intact
parathyroid hormone (iPTH) concentrations. Insulin resistance
was assessed using the HOMA-IR equation as follows:
HOMA-IR¼ ðfasting insulin in microunits per liter
fasting plasma glucose in mmol=L=22:5Þ ð1Þ
In addition, high-sensitivity C-reactive protein (hs-CRP)
concentrations were determined by a latex-enhanced immuno-
nephelometric method using a BNII analyzer (Dade Behring,
Newark, DE, USA). Kt/V urea was determined from the total loss
of urea nitrogen in spent dialysate using PD Adequest 2.0 for
Windows software (Baxter Healthcare, Deerﬁeld, IL, USA).
Follow-up and end points
Patients were followed up at 3-month intervals through
January 1, 2014. All deaths and hospitalizations were noted in a
serious adverse event database. All events were retrieved from
the database and carefully reviewed to determine incident
CVD. Primary outcomes were major cardiovascular events,
which were deﬁned as death or hospitalization from an acute
coronary syndrome and stable angina requiring coronary
revascularization or coronary artery bypass surgery. Cerebro-
vascular events were deﬁned as transient ischemic attack,
stroke, or carotid endarterectomy and peripheral vascular
disease deﬁned as ischemic limb loss and/or ulceration or
peripheral revascularization procedure that also included
major cardiovascular events. When a patient died within 60
days after transfer to HD, the death was regarded as a
mortality event. Loss to follow-up, kidney transplantation,
and transfer to HD were censored in the ﬁnal analysis.
Statistical analysis
Continuous variables were expressed as mean7standard
deviation, or median (interquartile range), whereas categorical
variables were expressed as a number (percentage). Normality
of distribution was ascertained by the Kolmogorov-Smirnov test.
Table 1. Baseline characteristics of patients according to the homeostatic model assessment of insulin resistance tertiles
Variables All (n¼201) 1st tertile (n¼67) 2nd tertile (n¼67) 3rd tertile (n¼67) P
Age (y) 53.178.3 52.278.8 52.378.0 54.677.9 0.16
Male 99 (49.3) 34 (50.8) 35 (52.2) 30 (44.8) 0.67
BMI (kg/m2) 23.473.0 22.672.3 23.373.0 24.473.5 0.002
% Lean body mass 72.5710.3 73.1710.7 72.6710.3 71.779.9 0.74
PD duration (mo) 83754.3 96.3754.5 71.2748.3 81.5757.6 0.027
Kt/V 2.070.4 2.070.5 2.070.4 2.070.3 0.93
Icodextrin use 90 (44.8) 31 (46.3) 30 (44.8) 29 (43.3) 0.94
Previous CVD* 34 (16.9) 8 (4.0) 12 (6.0) 14 (7.0) 0.37
IFG 32 (15.9) 4 (6.0) 9 (13.4) 19 (28.4) 0.001
New-onset DM 12 (6.0) 3 (1.5) 3 (1.5) 6 (3.0) 0.28
Smoker 49 (24.4) 16 (8.0) 20 (10.0) 13 (6.5) 0.37
Hemoglobin (g/dL) 10.571.5 10.371.6 10.871.6 10.671.3 0.12
BUN (mg/dL) 60.7719.0 61.6719.0 62.4719.4 58.2718.5 0.39
Creatinine (mg/dL) 11.973.4 12.473.7 11.673.4 11.773.2 0.35
Albumin (g/dL) 3.670.4 3.570.4 3.770.4 3.770.5 0.017
Total cholesterol (mg/dL) 182.1736.1 176.8736.9 183.8737.2 185.8734.1 0.32
Triglyceride (mg/dL) 140.67106.8 100.3752.1 137.2780.1 184.27147.9 < 0.001
HDL-C (mg/dL) 46.8713.5 47.9713.0 49.0714.1 43.5712.9 0.041
LDL-C (mg/dL) 108.5731.9 103.8729.2 111.5734.5 110.1731.7 0.34
Calcium (mg/dL) 9.070.8 8.970.7 9.070.7 9.171.0 0.41
Phosphate (mg/dL) 4.871.1 4.871.2 4.871.2 5.071.0 0.85
iPTH (pg/mL) (IQR) 262.5 (71.5–322.8) 254 (80.6–343.0) 281.3 (71.0–212.7) 252 (41.0–313.0) 0.91
log hs-CRP (mg/L) 0.270.8 0.270.8 0.270.7 0.370.8 0.67
Fasting glucose (mg/dL) 91.7715.3 86.8710.2 91.179.1 97.1721.6 < 0.001
Fasting insulin (mU/mL) 11.178.5 4.471.2 9.272.0 19.779.4 < 0.001
HOMA-IR 2.672.1 0.970.3 2.170.4 4.772.2 < 0.001
Medication
ACEi or ARB 178 (88.6) 62 (92.5) 58 (86.6) 58 (86.6) 0.46
Ca-based P-binder 163 (81.1) 56 (83.6) 53 (79.1) 53 (79.1) 0.42
Non Ca-based P-binder 40 (19.9) 13 (19.4) 12 (17.9) 15 (22.4) 0.34
Statin 25 (12.4) 7 (10.5) 7 (10.5) 11 (16.4) 0.48
* Cerebrovascular disease, coronary artery disease, peripheral artery disease.
Data are presented as n (%) or mean7SD, unless otherwise indicated.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; Ca, calcium;
CVD, cardiovascular disease; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin
resistance; hs-CRP, high-sensitivity c-reactive protein; IFG, impaired fasting glucose; iPTH, intact parathyroid hormone; IQR, interquartile range;
LDL-C, low-density lipoprotein cholesterol; P, phosphorus; PD, peritoneal dialysis; SD, standard deviation.
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value of their HOMA-IR. To compare the baseline characteristics,
analysis of variance or Kruskal-Wallis test and Chi-square tests
were used for continuous variables and categorical variables,
respectively. Univariate and multivariate linear regression ana-
lyses were performed to determine signiﬁcant factors associated
with HOMA-IR. Comparisons for major cardiovascular events
were performed by the Kaplan-Meier analysis and a log-rank
test. The independent predictive value of HOMA-IR for primary
outcome was conﬁrmed by Cox proportional hazards regression
models, which included signiﬁcant variables in univariate ana-
lysis. Statistical analysis was performed with SPSS for Windows
version 18.0 (SPSS Inc., Chicago, IL, USA). A P valueo0.05 was
considered signiﬁcant.Results
Demographic characteristics of patients
Baseline demographic and laboratory characteristics of
patients are detailed in Table 1. The mean age was 53.178.3
years and 99 patients (49.3%) were male. The mean value of
HOMA-IR was 2.672.1. Patients were divided into three groups
according to the tertile values of HOMA-IR. The three groups
showed no signiﬁcant differences in age, sex, previous history ofCVD, proportion of smokers, dialysis adequacy, icodextrin user,
total cholesterol, low-density lipoprotein cholesterol, log hs-CRP,
or medication including renin-angiotensin-aldosterone system
blockers or statin. However, BMI, impaired fasting glucose, and
TG were signiﬁcantly higher in the group with high HOMA-IR
compared to the middle and low HOMA-IR groups (P¼0.002,
P¼0.001, and Po0.001, respectively). Meanwhile, HDL-C was
signiﬁcantly lower in the high HOMA-IR group (P¼0.041).
Association between HOMA-IR and clinical and biochemical
parameters
In univariate analysis, HOMA-IR was positively associated
with BMI, previous history of CVD, TG, and serum calcium
level, but it was negatively associated with HDL-C (Table 2).
Multivariate linear regression analysis revealed that BMI,
previous CVD, and TG had independent associations with
HOMA-IR in patients on PD (Table 3).
HOMA-IR as an independent predictor of major
cardiovascular events
During a mean follow-up duration of 36.8716.2 months,
the primary outcome was observed in 36 patients (17.9%), and
12 patients (6.0%) died from a new-onset cardiovascular event.
The patients with cardiovascular events were signiﬁcantly
Table 3. Multivariate linear regression analysis for the association
of homeostasis model assessment-insulin resistance with clinical
and biochemical variables (n¼201)
Variables β P
Age 0.055 0.41
Female 0.037 0.58
Body mass index 0.169 0.011
Previous cardiovascular disease 0.137 0.029
Triglyceride 0.331 < 0.001
HDL-C 0.017 0.81
Calcium 0.121 0.07
HDL-C, high-density lipoprotein cholesterol.
Table 2. Univariate linear regression analysis for the association of
homeostasis model assessment-insulin resistance with clinical and
biochemical variables (n¼201)
Variables β P
Age 0.133 0.06
Female 0.041 0.57
Body mass index 0.222 0.002
% Lean body mass 0.068 0.34
Peritoneal dialysis duration 0.029 0.68
Kt/V 0.079 0.27
Previous cardiovascular disease 0.151 0.032
Smoker 0.059 0.41
Hemoglobin 0.034 0.63
BUN 0.96 0.18
Creatinine 0.009 0.90
Albumin 0.138 0.051
Total cholesterol 0.051 0.47
Triglyceride 0.421 < 0.001
HDL-C 0.16 0.023
LDL-C 0.002 0.98
Calcium 0.179 0.011
Phosphate 0.037 0.6
Intact parathyroid hormone 0.07 0.32
log hs-CRP 0.058 0.41
BUN, blood urea nitrogen; HDL-C, high-density lipoprotein cholesterol;
hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipopro-
tein cholesterol.
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The log hs-CRP and HOMA-IR were signiﬁcantly higher,
whereas % lean body mass (%LBM) was signiﬁcantly lower in
patients with new-onset cardiovascular events (Table 4). A
Kaplan-Meier plot showed that CVD event-free survival rates
were signiﬁcantly lower in the highest HOMA-IR tertile group
than in the lower two HOMA-IR groups (log-rank test;
P¼0.029; Fig. 2). However, there was no difference in CVD
event-free survival according to new onset diabetes (data not
shown). In univariate Cox proportional hazard analysis, age,
previous history of CVD, and log hs-CRP as well as HOMA-IR
levels were signiﬁcant risk factors for a primary outcome
(Table 5). In multivariate Cox analysis, HOMA-IR was a signiﬁ-
cant independent predictor of new-onset major cardiovascular
events (hazard ratio: 1.18, 95% conﬁdence interval: 1.03–1.35;
P¼0.014) after adjustment for age, sex, %LBM, previous CVD,
and log hs-CRP (Table 6).Discussion
In this observational study, we demonstrated that HOMA-IR
was closely correlated with the parameters of metabolic
syndrome such as BMI, impaired fasting glucose, and serum
TG level. In addition, increased HOMA-IR was signiﬁcantly
associated with new-onset cardiovascular events as well as
history of previous CVD. The current study showed that insulin
resistance, as assessed by HOMA-IR, might be a risk factor for
CVD in nondiabetic patients with prevalent PD.
Insulin resistance is a physiological circumstance in which
cells are not able to react with normal responses to the
hormonal effects of insulin. In the general population, several
factors including obesity, increased TG level, sedentary life-
style, and high-fat diet can induce insulin resistance [12,13].
Adipose tissue in obese patients secreted proinﬂammatory
cytokines and reduced insulin sensitivity [14]. In addition,
hyperleptinemia and decreased adiponectin levels inducedimpairment of insulin signaling [15]. A previous study
reported that high leptin and low adiponectin was prevalent
and signiﬁcantly associated with clinical outcomes in patients
with prevalent PD [16]. Decreased renal function is also
associated with insulin resistance in nondialysis chronic
kidney disease and ESRD patients. Kobayashi et al [17]
revealed that insulin resistance was linearly correlated with
the decline of renal function in patients with chronic kidney
disease. In addition to classic risk factors, chronic exposure to
high-glucose-containing dialysate and its degradation
products in patients with long-standing PD might exacerbate
a series of metabolic inﬂuences such as dyslipidemia, hyper-
glycemia, visceral obesity, and subsequently cause increases in
insulin resistance [7,8,18]. Furthermore, impaired fasting glu-
cose is associated with mortality in nondiabetic patients on PD
[19]. The current study also showed that HOMA-IR was
signiﬁcantly associated with components of metabolic
syndrome, such as BMI, impaired fasting glucose, and serum
TG level. Moreover, most of the study patients were anuric and
were patients on prevalent PD of relatively long duration.
Chronic exposure of high-glucose solution and the absence of
residual renal might have aggravated insulin resistance in
these study patients. Indeed, study patients have been main-
tained on PD with relatively long-standing duration, and we
did not collect the exact data on high glucose containing
dialysate including 2.5% or 4.25% solution. However, there
were no signiﬁcant differences in HOMA-IR according to use
of non-glucose-based PD solution.
The connection between CVD and insulin resistance is well
known, as they have been shown to be closely interrelated
[20–22]. Insulin resistance-related systemic inﬂammation and
oxidative stress also frequently accompanies cardiovascular
risk factors [23,24]. The combined effect of insulin resistance
and coexisting metabolic abnormality enhanced risks of
cardiovascular events. In the current study, we conﬁrmed that
insulin resistance was principally associated with BMI and
serum TG level as well as previous CVD. These markers
are basically associated with metabolic disarrangement, or
so-called “metabolic syndrome”, and thus, insulin resistance
is considered to be part of a “metabolic syndrome”. Especially
in patients with ESRD, metabolic disarrangement is more
prominent and causes more severe adverse events such as
cardiovascular disorder [25]. Our study showed that HOMA-IR
remained a signiﬁcant variable even after adjustment for
confounding variables, including hs-CRP. Based on this analy-
sis, insulin resistance is associated with CVD, independent of
systemic inﬂammation in patients on PD.
Chronic inﬂammation and protein-energy wasting play an
important role in the development of CVD in patients with
Table 4. Clinical characteristics of subjects according to new-onset cardiovascular event
Variables
New-onset CV event Without CV event
P
(n¼36) (n¼165)
Age (y) 57.977.5 52.078.1 < 0.001
Male 16 (44.4) 83 (50.3) 0.52
Body mass index (kg/m2) 2473.4 23.373.0 0.29
% Lean body mass 67.8710.1 73.5710.1 0.003
Peritoneal dialysis duration (mo) 87.7752.1 81.9754.9 0.56
Kt/V 2.070.3 2.070.4 0.83
Previous CVD* 11 (30.6) 23 (13.9) 0.016
New-onset DM 2 (1.0) 10 (5.0) 0.63
Smoker 6 (16.7) 43 (26.1) 0.23
Hemoglobin (g/dL) 10.471.5 10.671.5 0.42
BUN (mg/dL) 56.4717.0 61.7719.3 0.13
Creatinine (mg/dL) 11.373.3 12.073.4 0.27
Albumin (g/dL) 3.570.4 3.670.5 0.31
Total cholesterol (mg/dL) 181.0736.1 182.4736.2 0.84
Triglyceride (mg/dL) 136.4778.7 141.57112.2 0.8
HDL-C (mg/dL) 44.4712.5 47.3713.6 0.25
LDL-C (mg/dL) 113.6728.5 107.3732.6 0.29
Calcium (mg/dL) 9.071.0 9.070.8 0.91
Phosphate (mg/dL) 4.771.2 4.971.1 0.31
iPTH (pg/mL) 173.9 (71.5–32.9) 153.5 (53.4–454.1) 0.57
log hs-CRP (mg/L) 0.671.0 0.170.7 0.012
HOMA-IR 3.372.4 2.471.9 0.044
* Cerebrovascular disease, coronary artery disease, peripheral artery disease.
Data are presented as n (%) or mean 7 SD.
BUN, blood urea nitrogen; CVD, cardiovascular disease; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis
model assessment-insulin resistance; hs-CRP, high-sensitivity c-reactive protein; iPTH, intact parathyroid hormone; LDL-C, low-density lipoprotein
cholesterol; SD, standard deviation.
Figure 2. Kaplan-Meier plots for cardiovascular (CV) disease event-
free survival between the lower two tertiles and the highest tertile
group, according to the homeostatic model assessment of insulin
resistance (HOMA-IR).
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associated with atherosclerosis and poor clinical outcomes in
dialysis patients [26]. The paradoxical inverse association
between mortality and nutritional status in dialysis patients
is referred to as “reverse epidemiology” [27]. However,
recent studies demonstrated that not only malnutrition
but also obesity is associated with increased mortality in
dialysis patients undergoing PD [28]. Another study also
reported that obesity including visceral adiposity is associated
with insulin resistance and enhanced atherosclerosis in
this population [29]. Our study showed that insulin resistance
is closely associated with BMI and new-onset cardiova-
scular events. Taken together with previous and current
results, metabolic derangements, such as insulin resistance in
patients undergoing PD, are closely affected atherosclerotic
complications.Malnutrition-inﬂammation complex syndrome is a nontra-
ditional risk factor for CVD in ESRD. Serum albumin and %LMB
is a classic marker for malnutrition and is a strong risk factor of
mortality in dialysis patients [30–32]. We evaluated the clinical
signiﬁcance of serum albumin and %LBM for new-onset cardi-
ovascular events. The signiﬁcance of these parameters was
marginally valuable, although %LBM was a signiﬁcant risk factor
for CVD on univariate analysis. We had already excluded
patients with chronic inﬂammatory status and active infection
episodes and enrolled only relatively stable patients undergoing
PD. Moreover, serum albumin is associated not only with
inﬂammation but also ﬂuid status and peritoneal transport
status [33]. Based on the results of the current study, insulin
resistance, rather than malnutrition, was the primary contribu-
tor to the higher incidence of cardiovascular events in relatively
well-nourished patients on PD.
There are several limitations to this study. First, the study
patients were all Korean and undergoing prevalent PD at a single
center, and the duration of PD in the study population was
relatively diverse. Thus, selection bias is possible and there could
be some limitation in the euglycemic clamp for practical reasons.
Even though the accuracy of the euglycemic clamp is superior to
other methods, its invasiveness may cause it to be difﬁcult to use
for a large study population. The HOMA-IR method is easy to use
and results from HOMA-IR are usually consistent with results
acquired by the euglycemic clamp technique [34,35]. Finally, the
absence of sequential follow-up measurements of HOMA-IR was
another limitation in this study. A patient`s insulin resistance
might have changed during the follow-up period and time-
averaged levels are much more reliable. Although we did not
check HOMA-IR serially, however, we did enroll only patients on
PD who were relatively stable. In the future, measurement of
serial changes in insulin resistance would be helpful to improve
the quality of signiﬁcance in predicting prognosis.
Table 5. Univariate Cox regression analysis for the association of new-onset cardiovascular events with clinical and biochemical variables
(n¼201)
Variables Hazard ratio (95% CI) P
Age (per 1 y) 1.107 (1.059–1.158) < 0.001
Female 0.963 (0.497–1.867) 0.91
Body mass index (per 1 kg/m2) 1.094 (0.981–1.221) 0.11
% Lean body mass (per 1%) 0.953 (0.920–0.987) 0.008
Peritoneal dialysis duration (per 1 mo) 1.003 (0.997–1.009) 0.32
Kt/V (per 1) 0.867 (0.332–2.261) 0.77
Previous CVD 2.118 (1.042–4.308) 0.038
Smoker 0.656 (0.272–1.580) 0.35
Hemoglobin (per 1 g/dL) 0.875 (0.695–1.102) 0.26
BUN (per 1 mg/dL) 0.989 (0.969–1.009) 0.27
Creatinine (per 1 mg/dL) 0.964 (0.865–1.075) 0.51
Albumin (per 1 g/dL) 0.603 (0.275–1.326) 0.21
Total cholesterol (per 1 mg/dL) 0.998 (0.989–1.007) 0.65
Triglyceride (per 1 mg/dL) 0.999 (0.996–1.003) 0.66
HDL-C (per 1 mg/dL) 0.979 (0.953–1.006) 0.13
LDL-C (per 1 mg/dL) 1.002 (0.993–1.012) 0.62
Calcium (per 1 mg/dL) 1.005 (0.667–1.514) 0.98
Phosphate (per 1 mg/dL) 0.885 (0.675–1.161) 0.38
iPTH (per 1 pg/mL) 1.000 (0.999–1.001) 0.54
log hs-CRP (per 1 mg/L) 1.850 (1.320–2.593) < 0.001
HOMA-IR (per 1) 1.180 (1.045–1.332) 0.008
BUN, blood urea nitrogen; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-
insulin resistance; hs-CRP, high-sensitivity c-reactive protein; iPTH, intact parathyroid hormone; LDL-C, low-density lipoprotein cholesterol.
Table 6. Multivariate Cox regression analysis for the association of
new-onset cardiovascular events with clinical and biochemical
variables (n¼201)
Variables Hazard ratio (95% CI) P
Age (per 1 y) 1.092 (1.035–1.152) 0.001
Female 0.685 (0.310–1.511) 0.35
% Lean body mass (per 1%) 0.978 (0.931–1.027) 0.37
Previous CVD* 1.534 (0.690–3.410) 0.29
log hs-CRP (per 1 mg/L) 2.286 (0.907–2.127) 0.13
HOMA-IR (per 1) 1.180 (1.034–1.348) 0.014
* Cerebrovascular disease, coronary artery disease, peripheral artery
disease.
CI, conﬁdence interval; CVD, cardiovascular disease; HOMA-IR, home-
ostasis model assessment-insulin resistance; hs-CRP, high-sensitivity
c-reactive protein.
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